var data={"title":"Ethanol (topical and injection): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ethanol (topical and injection): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5579?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ethanol-topical-and-injection-drug-information\" class=\"drug drug_general\">see &quot;Ethanol (topical and injection): Drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131116\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Epi-Clenz [OTC];</li>\n      <li>GelRite [OTC];</li>\n      <li>Isagel [OTC];</li>\n      <li>Lavacol [OTC];</li>\n      <li>Prevacare [OTC];</li>\n      <li>ProtecTeaV [OTC];</li>\n      <li>Purell Advanced [OTC];</li>\n      <li>Purell [OTC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131117\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Biobase;</li>\n      <li>Biobase-G</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056328\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Anti-infective Agent, Topical</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antidote, Ethylene Glycol Toxicity</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antidote, Methanol Toxicity</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Fat Occlusion (Central Venous Catheter), Treatment Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Neurolytic</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056321\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=ethanol-topical-and-injection-drug-information\" class=\"drug drug_general\">see &quot;Ethanol (topical and injection): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Antiseptic: </b> Children and Adolescents: Ethyl rubbing alcohol: Topical: Apply 1 to 3 times daily as needed </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Methanol or ethylene glycol ingestion:</b> Limited data available (Barceloux 1999; Barceloux 2002): Infants, Children, and Adolescents: <b>Note:</b> IV administration is the preferred route; continue therapy until ethylene glycol and/or methanol is no longer detected or levels are &lt;20 mg/dL <b>and</b> the patient is asymptomatic <b>and</b> metabolic acidosis has been corrected. If ethylene glycol and/or methanol levels are not available in a timely manner, continue therapy until the estimated time of clearance of ethylene glycol and/or methanol has elapsed <b>and</b> the patient is asymptomatic with a normal pH. If patient has coingested ethanol, measure the baseline serum ethanol concentration and adjust the ethyl alcohol loading dose based on results to achieve a serum ethanol level of ~100 mg/dL. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Absolute ethyl alcohol [98% (196 proof) = 77.4 g EtOH/dL]:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: <b>Note:</b> Contact the Poison Control Center for options related to compounding IV ethanol. </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Initial: 600 to 700 mg/kg [equivalent to 7.6 to 8.9 mL/kg using a 10% solution]</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Maintenance (not receiving hemodialysis): Goal of therapy is to maintain serum ethanol levels &gt;100 mg/dL. </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Nondrinker: 66 mg/kg/hour [equivalent to 0.83 mL/kg/hour using a <b>10% solution</b>] </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Chronic drinker: 154 mg/kg/hour [equivalent to 1.96 mL/kg/hour using a <b>10% solution</b>] </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral: <b>Note:</b> Solution must be diluted to a &le;20% concentration with water or juice and administered orally or via a nasogastric tube. </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Initial: 600 to 700 mg/kg (equivalent to 0.78 to 0.9 mL/kg using a <b>98% solution</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Maintenance (not receiving hemodialysis): Goal of therapy is to maintain serum ethanol levels &gt;100 mg/dL </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Nondrinker: 66 mg/kg/hour (equivalent to 0.09 mL/kg/hour using a <b>98% solution</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Chronic drinker: 154 mg/kg/hour (equivalent to 0.20 mL/kg/hour using a <b>98% solution</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Central venous catheter lock:</b> Limited data available: Infants, Children, and Adolescents: See institution-based protocol: Dehydrated alcohol injection: I.V.: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Catheter-related blood stream infection (CRBSI):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Prophylaxis:</i>  <b>Note:</b> Use suggested in patients with long term catheters with a history of multiple CRBSI episode (IDSA [O&rsquo;Grady 2011]); dosing regimens variable: 70% ethanol; instill a volume equal to the internal volume of the catheter once daily with a dwell time of 2 to 14 hours; withdraw ethanol at the end of the dwell time (Cober 2011; Mouw 2008; Wales 2011). Less frequent dosing (3 times per week) for a minimum 4 hour dwell time (Jones 2010) and once weekly dosing with a 2-hour dwell time (Pieroni 2013) have also shown to produce statistically significant reductions in infection rate and catheter loss; most study subjects were receiving long-term outpatient cyclic parenteral nutrition. However, a small case-series observed an increase in infection rate when the frequency of ethanol locks were decreased to less than daily (eg, twice weekly or once weekly; dwell times not specified) during an ethanol shortage; all patients in this study had tunneled silastic catheters (Ralls 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Treatment:</i> Dosing regimens variable: 70% ethanol; instill a volume equal to the internal volume of the catheter with a dwell time 4 to 25 hours; some protocols utilized single dose and others repeated the dose once daily for 3 to 5 days; dosing should be repeated for each lumen and used in combination with systemic antimicrobials (Danneberg 2003; McGrath 2011; Onland 2006; Valentine 2011). For fungal bloodstream infection, case-reports describe success using once daily with dwell times of 2 to 24 hours for 14 days following the patient's first negative blood culture (Blackwood 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Fat occlusion of central venous catheters: Dehydrated alcohol injection: Up to 3 mL of 70% ethanol (maximum: 0.55 mL/kg); instill a volume equal to the internal volume of the catheter; may repeat if patency not restored after 30 to 60 minute dwell time; if dose repeated, reassess after 4-hour dwell time (Pennington 1987; Werlin 1995).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Antiseptic:</b> Ethyl rubbing alcohol: Topical: Apply 1 to 3 times daily as needed </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Therapeutic neurolysis (nerve or ganglion block):</b> Dehydrated alcohol injection 98%: Intraneural: Dosage variable depending upon the site of injection (eg, trigeminal neuralgia: 0.05 to 0.5 mL as a single injection per interspace vs subarachnoid injection: 0.5 to 1 mL as a single injection per interspace); single doses &gt;1.5 mL are seldom required. <b>Note:</b> Administer when pain is from malignant origin only.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Replenishment of fluid and carbohydrate calories:</b> Dehydrated alcohol infusion: Alcohol 5% and dextrose 5%: 1,000 to 2,000 mL/day by slow infusion</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling. Hemodialysis clearance: 300 to 400 mL/minute with an ethanol removal rate of 280 mg/minute.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Methanol or ethylene glycol ingestion: Infants, Children, Adolescents, and Adults: Absolute ethyl alcohol: Dosage adjustment for hemodialysis: Maintenance dose: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Nondrinker: 169 mg/kg/hour (equivalent to 2.13 mL/kg/hour using a <b>10% solution</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Chronic drinker: 257 mg/kg/hour (equivalent to 3.26 mL/kg/hour using a <b>10% solution</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Nondrinker: 169 mg/kg/hour (equivalent to 0.22 mL/kg/hour using a <b>98% solution</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Chronic drinker: 257 mg/kg/hour (equivalent to 0.33 mL/kg/hour using a <b>98% solution</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131096\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aerosol, foam, topical [instant hand sanitizer]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Epi-Clenz: 62% (240 mL, 480 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Foam, topical [instant hand sanitizer]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Purell Advanced: 70% (45 mL, 535 mL, 700 mL, 1200 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gel, topical [instant hand sanitizer]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Epi-Clenz: 70% (45 mL, 120 mL, 480 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Epi-Clenz Plus: 62% (45 mL, 800 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">GelRite: 62% (120 mL, 480 mL, 800 mL, 1000 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Isagel: 60% (59 mL, 118 mL, 621 mL, 800 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Prevacare: 60% (120 mL, 240 mL, 960 mL, 1200 mL, 1500 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ProtecTeaV: 70% (236 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Purell: 62% (15 mL, 30 mL, 59 mL, 60 mL, 120 mL, 236 mL, 240 mL, 250 mL, 360 mL, 500 mL, 800 mL, 1000 mL, 2000 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Purell Advanced: 70% (30 mL, 236 mL, 1000 mL, 2000 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, solution [dehydrated, preservative free]: 98% (1 mL, 5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Liquid, topical [denatured]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lavacol: 70% (473 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Generic: 70% (480 mL, 3840 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pad, topical [instant hand sanitizer/towelette]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Isagel: 60% (50s, 300s)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Purell: 62% (24s, 35s, 40s, 100s, 120s, 175s, 1000s, 4000s)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131086\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056332\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: Ethylene glycol or methanol poisoning: After diluting ethyl alcohol (98% ethanol injection solution) to &le;20% solution, administer hourly by mouth or via nasogastric tube. Out-of-hospital management with orally administered ethanol is not recommended. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Not for SubQ administration; IV: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ethylene glycol or methanol poisoning: After diluting ethyl alcohol (98% ethanol injection solution) to 10% v/v solution, infuse initial dose over 60 minutes; central vein is the preferred route. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Occluded central venous catheter/central venous catheter lock: After diluting ethyl alcohol (98% ethanol injection solution) to 70% solution, instill with a volume equal to the internal volume of the catheter; assess patency at 30 to 60 minutes (or per institutional protocol); may repeat. Ensure adequate measurement of catheter volume to ensure adequate coverage of line and no excess ethanol is administered. Ethanol forms a visual precipitate with heparin or citrate, flush catheter well with normal saline before administration. (Cober 2007; Cober 2011) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intraneural: Adult: Separate needles should be used for each of multiple injections or sites to prevent residual alcohol deposition at sites not intended for tissue destruction; inject slowly after determining proper placement of needle; since dehydrated alcohol is hypobaric when compared with spinal fluid, proper positioning of the patient is essential to control localization of injections into the subarachnoid space </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25188563\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;\">Store at room temperature; do not use unless solution is clear and container is intact. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056331\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Therapeutic neurolysis of nerves or ganglia for the relief of intractable, chronic pain in such conditions as inoperable cancer and trigeminal neuralgia (dehydrated alcohol injection) (FDA approved in adults); epidural or individual motor nerve injections to control certain manifestations of cerebral palsy and spastic paraplegia, celiac plexus block to relieve pain of inoperable upper abdominal cancer, and intra- and subcutaneously for relief of intractable pruritis ani (diluted [40% to 50%] dehydrated alcohol injection: FDA approved in adults); has also been used as an antidote for the treatment of methanol and ethylene glycol intoxication, as a lock solution for the prevention and treatment of catheter related infections, and for treatment of occluded central venous catheters due to lipid deposition from fat emulsion infusion (particularly 3-in-1 admixture) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topical: Skin antiseptic (hand sanitizer gels, foams solutions and rubbing ethyl alcohol: FDA approved pediatric patients [age not specified] and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131139\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Ethanol may be confused with Ethyol, Ethamolin</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131138\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Flushing, hypotension, phlebitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Agitation, alcohol intoxication, brain disease, central nervous system depression, coma, disorientation, drowsiness, headache, neuropathy, sedation, seizure (rare), vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hypoglycemia </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Gastric irritation, nausea, vomiting </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Urinary retention </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Tissue damage</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Polyuria </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131102\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to ethyl alcohol or any component of the formulation; seizure disorder and diabetic coma; subarachnoid injection of dehydrated alcohol in patients receiving anticoagulants; pregnancy (prolonged use or high doses at term)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131090\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus; ethyl alcohol may decrease blood sugar.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Gout: Use with caution in patients with gout.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Shock: Use with caution in patients with shock.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cranial surgery: Use with caution in patients following cranial surgery.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Infants: Minimize dermal exposure of ethyl alcohol in infants as significant systemic absorption and toxicity can occur. Ethyl alcohol passes freely into breast milk at a level approximately equivalent to maternal serum level.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pregnancy: Use with caution in pregnant women with anticipated postpartum hemorrhage.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Administration: Proper positioning of the patient for neurolytic administration is essential to control localization of the injection of dehydrated alcohol (which is hypobaric) into the subarachnoid space; avoid extravasation. Not for SubQ administration. Do not administer simultaneously with blood due to the possibility of pseudoagglutination or hemolysis; may potentiate severe hypoprothrombic bleeding. Avoid extravasation during IV administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: When used as a topical antiseptic, improper use may lead to product contamination. Although infrequent, product contamination has been associated with reports of localized and systemic infections. To reduce the risk of infection, ensure antiseptic products are used according to the labeled instructions; avoid diluting products after opening; and apply single-use containers only one time to one patient and discard any unused solution (FDA Drug Safety Communication, 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Monitoring: Clinical evaluation and periodic lab determinations, including serum ethanol levels, are necessary to monitor effectiveness, changes in electrolyte concentrations, and acid-base balance (when used as an antidote). Monitor blood glucose closely, particularly in children as treatment of ingestions is associated with hypoglycemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Proper storage: Flammable liquid and should be kept cool and away from any heat source.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298697\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Induces</b> UGT1A1</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6217619\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13289&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acetaminophen: Alcohol (Ethyl) may enhance the hepatotoxic effect of Acetaminophen. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acetohydroxamic Acid: Alcohol (Ethyl) may enhance the adverse/toxic effect of Acetohydroxamic Acid. Specifically, Alcohol (Ethyl) may increase the risk of Acetohydroxamic Acid associated rash. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acitretin: Alcohol (Ethyl) may enhance the teratogenic effect of Acitretin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Agomelatine: Alcohol (Ethyl) may enhance the adverse/toxic effect of Agomelatine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha-Lipoic Acid: Alcohol (Ethyl) may diminish the therapeutic effect of Alpha-Lipoic Acid. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amantadine: Alcohol (Ethyl) may enhance the CNS depressant effect of Amantadine. Alcohol may also cause dose-dumping for at least one extended-release amantadine product. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminophylline: Alcohol (Ethyl) may increase the serum concentration of Aminophylline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amisulpride: May enhance the adverse/toxic effect of Alcohol (Ethyl).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Armodafinil: Alcohol (Ethyl) may diminish the therapeutic effect of Armodafinil. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aspirin: Alcohol (Ethyl) may enhance the adverse/toxic effect of Aspirin. Specifically, alcohol may increase the bleeding risk of aspirin. Alcohol (Ethyl) may diminish the therapeutic effect of Aspirin. Specifically, alcohol may interfere with the controlled release mechanism of extended release aspirin.  Management: Monitor patients who drink 3 or more alcoholic drinks a day for increased bleeding while taking aspirin. Counsel patients about the risk of bleeding and discourage such consumption. Give extended release aspirin 2 hours before, or 1 hour after, alcohol.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): Alcohol (Ethyl) may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Systemic): Alcohol (Ethyl) may enhance the sedative effect of Azelastine (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bedaquiline: Alcohol (Ethyl) may enhance the hepatotoxic effect of Bedaquiline. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benznidazole: May enhance the adverse/toxic effect of Alcohol (Ethyl). A disulfiram-like reaction may occur.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Biperiden: Alcohol (Ethyl) may enhance the adverse/toxic effect of Biperiden. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brivaracetam: Alcohol (Ethyl) may enhance the CNS depressant effect of Brivaracetam. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromocriptine: Alcohol (Ethyl) may enhance the adverse/toxic effect of Bromocriptine. Bromocriptine may enhance the adverse/toxic effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the sedative effect of Alcohol (Ethyl).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: Alcohol (Ethyl) may enhance the CNS depressant effect of Buprenorphine.  Management: Advise patients receiving buprenorphine about the increased risk of CNS depression if they consume alcohol.  Consider alternatives to buprenorphine for opioid addiction treatment in patients who are dependent on alcohol.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: Alcohol (Ethyl) may enhance the adverse/toxic effect of BuPROPion. Specifically, seizure threshold may be lowered. BuPROPion may enhance the adverse/toxic effect of Alcohol (Ethyl). Specifically, alcohol tolerance may decrease during treatment.  Management: Patients receiving bupropion should be advised to minimize or avoid alcohol consumption due to possible lower alcohol tolerance, and lower seizure threshold associated with heavy alcohol consumption/abrupt discontinuation of heavy consumption.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of Alcohol (Ethyl).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefminox: May enhance the adverse/toxic effect of Alcohol (Ethyl).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefoperazone: May enhance the adverse/toxic effect of Alcohol (Ethyl).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CefoTEtan: May enhance the adverse/toxic effect of Alcohol (Ethyl).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Systemic): May enhance the adverse/toxic effect of Alcohol (Ethyl).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: Alcohol (Ethyl) may enhance the CNS depressant effect of Chlormethiazole. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: Alcohol (Ethyl) may enhance the adverse/toxic effect of Chlorphenesin Carbamate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cisapride: May enhance the adverse/toxic effect of Alcohol (Ethyl). Specifically, Alcohol (Ethyl) sedative and psychomotor effects may be enhanced.  Alcohol (Ethyl) may also worsen nocturnal heartburn. Cisapride may increase the serum concentration of Alcohol (Ethyl).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloBAZam: Alcohol (Ethyl) may enhance the CNS depressant effect of CloBAZam. Alcohol (Ethyl) may increase the serum concentration of CloBAZam. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the CNS depressant effect of Alcohol (Ethyl).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSERINE: Alcohol (Ethyl) may enhance the neurotoxic effect of CycloSERINE. Specifically, the risk for seizures may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyproterone: Alcohol (Ethyl) may diminish the therapeutic effect of Cyproterone. More specifically, alcohol may interfere with antiandrogenic effects of Cyproterone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cysteamine (Systemic): Alcohol (Ethyl) may enhance the adverse/toxic effect of Cysteamine (Systemic). Alcohol (Ethyl) may diminish the therapeutic effect of Cysteamine (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapoxetine: May enhance the adverse/toxic effect of Alcohol (Ethyl).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexlansoprazole: Alcohol (Ethyl) may decrease the serum concentration of Dexlansoprazole. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Didanosine: Alcohol (Ethyl) may enhance the adverse/toxic effect of Didanosine. Specifically, the risk of pancreatitis may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diethylpropion: Alcohol (Ethyl) may enhance the adverse/toxic effect of Diethylpropion. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of Alcohol (Ethyl).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Disulfiram: May enhance the adverse/toxic effect of Alcohol (Ethyl). A disulfiram-like reaction may occur.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxylamine: Alcohol (Ethyl) may enhance the CNS depressant effect of Doxylamine.  Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with alcohol is  not recommended<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of Alcohol (Ethyl).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Efavirenz: May enhance the adverse/toxic effect of Alcohol (Ethyl). Efavirenz may decrease the serum concentration of Alcohol (Ethyl).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eluxadoline: Alcohol (Ethyl) may enhance the adverse/toxic effect of Eluxadoline. Specifically, alcohol use may increase the risk of pancreatitis. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ethionamide: Alcohol (Ethyl) may enhance the adverse/toxic effect of Ethionamide. Specifically, there may be a risk for a psychotic episode/reaction. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ezogabine: Alcohol (Ethyl) may enhance the adverse/toxic effect of Ezogabine. Alcohol (Ethyl) may increase the serum concentration of Ezogabine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fesoterodine: Alcohol (Ethyl) may enhance the CNS depressant effect of Fesoterodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flibanserin: Alcohol (Ethyl) may enhance the hypotensive effect of Flibanserin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: Alcohol (Ethyl) may enhance the CNS depressant effect of Flunitrazepam. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: Alcohol (Ethyl) may enhance the CNS depressant effect of Fosphenytoin. Alcohol (Ethyl) may decrease the serum concentration of Fosphenytoin. This may be particularly applicable with chronic, heavy alcohol consumption. Alcohol (Ethyl) may increase the serum concentration of Fosphenytoin. This may be particularly applicable with acute, heavy alcohol consumption. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gabapentin Enacarbil: Alcohol (Ethyl) may enhance the CNS depressant effect of Gabapentin Enacarbil. Alcohol (Ethyl) may increase the absorption of Gabapentin Enacarbil. Specifically, the rate of absorption may be enhanced, as alcohol may speed the release of drug from the extended-release tablet. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Griseofulvin: May enhance the adverse/toxic effect of Alcohol (Ethyl). A disulfiram-like reaction may occur.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">GuanFACINE: Alcohol (Ethyl) may enhance the CNS depressant effect of GuanFACINE. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: Alcohol (Ethyl) may enhance the CNS depressant effect of HYDROcodone. Alcohol (Ethyl) may increase the serum concentration of HYDROcodone.  Management: Patients using the Zohydro ER brand of extended-release hydrocodone must not consume alcohol or alcohol-containing products due to possibly fatal outcomes. Other hydrocodone products are also expected to interact, but to a less significant degree.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indoramin: Alcohol (Ethyl) may enhance the sedative effect of Indoramin. Alcohol (Ethyl) may increase the serum concentration of Indoramin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ISOtretinoin: Alcohol (Ethyl) may enhance the adverse/toxic effect of ISOtretinoin. Specifically, the risk for elevated triglyceride concentrations may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketoconazole (Systemic): May enhance the adverse/toxic effect of Alcohol (Ethyl). Management: Advise patients to avoid alcohol ingestion while taking ketoconazole.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lercanidipine: Alcohol (Ethyl) may enhance the vasodilatory effect of Lercanidipine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levomilnacipran: Alcohol (Ethyl) may increase the absorption of Levomilnacipran. More specifically, Alcohol (Ethyl) may cause more rapid release of Levomilnacipran from extended-release tablets, which could accelerate absorption early post-dose.  Management: Avoid administering levomilnacipran with alcohol.  The use of alcohol in patients receiving levomilnacipran is not otherwise advised against, although it may theoretically modify the central effects of one or both drugs.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levosulpiride: Alcohol (Ethyl) may enhance the CNS depressant effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lomitapide: Alcohol (Ethyl) may enhance the hepatotoxic effect of Lomitapide.  Management: Advise patients to limit alcohol consumption to 1 drink per day while receiving lomitapide.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: Alcohol (Ethyl) may enhance the CNS depressant effect of Lormetazepam. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mecamylamine: Alcohol (Ethyl) may enhance the adverse/toxic effect of Mecamylamine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Melatonin: Alcohol (Ethyl) may enhance the adverse/toxic effect of Melatonin. Alcohol (Ethyl) may diminish the therapeutic effect of Melatonin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mequitazine: Alcohol (Ethyl) may enhance the CNS depressant effect of Mequitazine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetFORMIN: Alcohol (Ethyl) may enhance the adverse/toxic effect of MetFORMIN. Specifically, alcohol may potentiate the risk of lactic acidosis <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methadone: Alcohol (Ethyl) may enhance the CNS depressant effect of Methadone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: Alcohol (Ethyl) may enhance the adverse/toxic effect of Methylphenidate. Alcohol (Ethyl) may increase the serum concentration of Methylphenidate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetroNIDAZOLE (Systemic): May enhance the adverse/toxic effect of Alcohol (Ethyl). A disulfiram-like reaction may occur.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetroNIDAZOLE (Topical): May enhance the adverse/toxic effect of Alcohol (Ethyl). A disulfiram-like reaction may occur. Management: Warn patients and monitor for signs and symptoms of a disulfiram-like reaction if patients consume alcohol while using topical metronidazole. Some manufacturers of vaginal metronidazole products list alcohol use within 24 to 72 hours as a contraindication<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: Alcohol (Ethyl) may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mianserin: May enhance the CNS depressant effect of Alcohol (Ethyl).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mipomersen: Alcohol (Ethyl) may enhance the hepatotoxic effect of Mipomersen.  Management: Patients being treated with mipomersen should limit their consumption of alcohol to a maximum of 1 drink (or equivalent) per day.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirtazapine: Alcohol (Ethyl) may enhance the CNS depressant effect of Mirtazapine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Modafinil: Alcohol (Ethyl) may diminish the therapeutic effect of Modafinil. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Alcohol (Ethyl).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: Alcohol (Ethyl) may enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Morniflumate: Alcohol (Ethyl) may enhance the adverse/toxic effect of Morniflumate. Specifically, consumption of more than 3 alcoholic drinks per day may increase the risk of gastrointestinal hemorrhage during Morniflumate treatment. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of Alcohol (Ethyl).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nefopam: Alcohol (Ethyl) may enhance the CNS depressant effect of Nefopam. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Niacin: Alcohol (Ethyl) may enhance the adverse/toxic effect of Niacin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Niclosamide: May increase the absorption of Alcohol (Ethyl).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: Alcohol (Ethyl) may enhance the hypotensive effect of Nicorandil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NIFEdipine: Alcohol (Ethyl) may increase the serum concentration of NIFEdipine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nilutamide: May enhance the adverse/toxic effect of Alcohol (Ethyl). Specifically, nilutamide may increase the likelihood of alcohol intolerance (eg, facial flushing, malaise, hypotension).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: Alcohol (Ethyl) may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of GI bleeding may be increased with this combination. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir: Alcohol (Ethyl) may diminish the therapeutic effect of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir.  Management: Avoid alcohol consumption within 4 hours of taking the extended-release ombitasvir/paritaprevir/ritonavir/dasabuvir product. This interaction does not apply to the immediate-release ombitasvir/paritaprevir/ritonavir/dasabuvir product.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.  Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: Alcohol (Ethyl) may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OXcarbazepine: Alcohol (Ethyl) may enhance the CNS depressant effect of OXcarbazepine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxybutynin: Alcohol (Ethyl) may enhance the CNS depressant effect of Oxybutynin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: Alcohol (Ethyl) may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of Alcohol (Ethyl). Alcohol may also worsen the negative behavioral and psychiatric effects of Perampanel.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phendimetrazine: Alcohol (Ethyl) may enhance the adverse/toxic effect of Phendimetrazine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pheniramine: Alcohol (Ethyl) may enhance the CNS depressant effect of Pheniramine. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phentermine: Alcohol (Ethyl) may enhance the adverse/toxic effect of Phentermine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: Alcohol (Ethyl) may enhance the CNS depressant effect of Phenytoin. Alcohol (Ethyl) may increase the serum concentration of Phenytoin. This may be particularly applicable with acute, heavy alcohol consumption. Alcohol (Ethyl) may decrease the serum concentration of Phenytoin. This may be particularly applicable with chronic, heavy alcohol consumption. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: Alcohol (Ethyl) may enhance the hypotensive effect of Phosphodiesterase 5 Inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pipamperone [INT]: May enhance the adverse/toxic effect of Alcohol (Ethyl). Specifically, sedative and psychomotor effects may be enhanced.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: Alcohol (Ethyl) may enhance the sedative effect of Piribedil. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramipexole: Alcohol (Ethyl) may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propacetamol: Alcohol (Ethyl) may enhance the hepatotoxic effect of Propacetamol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propranolol: Alcohol (Ethyl) may decrease the serum concentration of Propranolol. Alcohol (Ethyl) may increase the serum concentration of Propranolol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prothionamide: Alcohol (Ethyl) may enhance the adverse/toxic effect of Prothionamide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: Alcohol (Ethyl) may enhance the adverse/toxic effect of Quinagolide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rilmenidine: Alcohol (Ethyl) may enhance the adverse/toxic effect of Rilmenidine. Specifically, alcohol increased the CNS depressant effect of rilmenidine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: Alcohol (Ethyl) may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rotigotine: Alcohol (Ethyl) may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: Alcohol (Ethyl) may enhance the adverse/toxic effect of Rufinamide. Specifically, sleepiness and dizziness may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: Alcohol (Ethyl) may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.  Management: Patients receiving selective serotonin reuptake inhibitors should be advised to avoid alcohol.  Monitor for increased psychomotor impairment in patients who consume alcohol during treatment with selective serotonin reuptake inhibitors.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin/Norepinephrine Reuptake Inhibitors: Alcohol (Ethyl) may enhance the adverse/toxic effect of Serotonin/Norepinephrine Reuptake Inhibitors. Specifically, risks of psychomotor impairment may be enhanced. Alcohol (Ethyl) may enhance the hepatotoxic effect of Serotonin/Norepinephrine Reuptake Inhibitors. Particularly duloxetine and milnacipran.  Management: Patients receiving serotonin/norepinephrine reuptake inhibitors (SNRIs) should be advised to avoid alcohol.  Monitor for increased psychomotor impairment and hepatotoxicity in patients who consume alcohol during treatment with SNRIs.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: Alcohol (Ethyl) may enhance the CNS depressant effect of Sodium Oxybate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May enhance the sedative effect of Alcohol (Ethyl).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfonylureas: May enhance the adverse/toxic effect of Alcohol (Ethyl). A flushing reaction may occur.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulpiride: Alcohol (Ethyl) may enhance the adverse/toxic effect of Sulpiride. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulthiame: May enhance the adverse/toxic effect of Alcohol (Ethyl). Specifically, concurrent use may result in a disulfiram-like reaction.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: Alcohol (Ethyl) may enhance the CNS depressant effect of Suvorexant. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): Alcohol (Ethyl) may increase the absorption of Tacrolimus (Systemic). More specifically, the initial absorption rate may be increased, as alcohol may speed the release of tacrolimus from extended-release tablets.  Management: Advise patients receiving extended-release tacrolimus (Astagraf XL or Envarsus XR brands) not to take the medication with alcoholic beverages.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the dermatologic adverse effect of Alcohol (Ethyl).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: Alcohol (Ethyl) may enhance the CNS depressant effect of Tapentadol. Alcohol (Ethyl) may increase the serum concentration of Tapentadol. Specifically, alcohol may increase the maximum serum concentrations when used with extended-release tapentadol. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of Alcohol (Ethyl).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline: Alcohol (Ethyl) may increase the serum concentration of Theophylline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: Alcohol (Ethyl) may enhance the orthostatic hypotensive effect of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tinidazole: May enhance the adverse/toxic effect of Alcohol (Ethyl). A disulfiram-like reaction may occur.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topiramate: Alcohol (Ethyl) may enhance the CNS depressant effect of Topiramate. Alcohol (Ethyl) may increase the serum concentration of Topiramate. This applies specifically to use with the extended-release topiramate capsules (Trokendi XR).  Also, topiramate concentrations may be subtherapeutic in the later portion of the dosage interval.  Management: Concurrent use of alcohol within 6 hours of ingestion of extended-release topiramate (Trokendi XR) is contraindicated.  Any use of alcohol with topiramate should be avoided when possible and should only be undertaken with extreme caution.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trabectedin: Alcohol (Ethyl) may enhance the hepatotoxic effect of Trabectedin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TraZODone: Alcohol (Ethyl) may enhance the adverse/toxic effect of TraZODone. Specifically, effects on sleepiness, dizziness, and manual dexterity may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Treprostinil: Alcohol (Ethyl) may increase the absorption of Treprostinil. Specifically, a more rapid and/or complete absorption of Treprostinil from extended-release tablets is possible.  Management: Avoid administration of treprostinil extended release tablets with alcohol, and advise patients to avoid this combination.  No such interaction is expected with other treprostinil formulations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimethobenzamide: Alcohol (Ethyl) may enhance the CNS depressant effect of Trimethobenzamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trospium: Alcohol (Ethyl) may enhance the CNS depressant effect of Trospium. Alcohol (Ethyl) may increase the serum concentration of Trospium. Specifically, alcohol may increase the peak (maximum) serum concentration of trospium when consumed within 2 hours of taking extended-release trospium.  Management: Avoid consuming any alcohol within 2 hours of taking a dose of trospium XR.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Varenicline: May enhance the adverse/toxic effect of Alcohol (Ethyl). Specifically, alcohol tolerance may be decreased and the risk for neuropsychiatric adverse effects may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vasodilators (Organic Nitrates): Alcohol (Ethyl) may enhance the vasodilatory effect of Vasodilators (Organic Nitrates). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Verapamil: May increase the serum concentration of Alcohol (Ethyl).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Alcohol (Ethyl) may decrease the serum concentration of Vitamin K Antagonists. More specifically, this effect has been described in heavy drinking alcoholic patients (over 250 g alcohol daily for over 3 months).  The role of alcohol itself is unclear. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zopiclone: Alcohol (Ethyl) may enhance the adverse/toxic effect of Zopiclone. Specifically, taking alcohol with zopiclone may increase the risk of complex sleep-related behaviors (eg, sleep-driving, eating food, making phone calls, leaving the house, etc.) Alcohol (Ethyl) may enhance the CNS depressant effect of Zopiclone. <i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131093\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (injection) (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131105\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted with alcohol injection. Ethanol crosses the placenta, enters the fetal circulation, and has teratogenic effects in humans (AAP 2000; Barceloux 1999). The following withdrawal symptoms have been noted in the neonate following maternal ethanol consumption during pregnancy: Crying, hyperactivity, irritability, poor suck, tremors, seizures, poor sleeping pattern, hyperphagia, and diaphoresis (Hudak 2014). Fetal alcohol syndrome (FAS) is a term referring to a combination of physical, behavioral, and cognitive abnormalities resulting from ethanol exposure during fetal development. Since a &quot;safe&quot; amount of ethanol consumption during pregnancy has not been determined, the AAP recommends those women who are pregnant or planning a pregnancy refrain from all ethanol intake (AAP 2000). When used as an antidote during the second or third trimester, FAS is not likely to occur due to the short treatment period; use during the first trimester is controversial (Barceloux 1999). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056327\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Antidotal therapy: Blood ethanol levels (at the end of the loading dose, every 1 to 2 hours until stabilized, and then every 2 to 4 hours thereafter); blood glucose, electrolytes (including serum magnesium), arterial pH, blood gases, methanol or ethylene glycol blood levels, heart rate, blood pressure</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056330\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Symptoms associated with serum ethanol levels: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nausea and vomiting: Serum level &gt;100 mg/dL </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Coma: Serum level &gt;300 mg/dL </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Antidote for methanol/ethylene glycol: Goal range: Blood ethanol level: 100-150 mg/dL (22-32 mmol/liter)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131089\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">When used to treat ethylene glycol or methanol toxicity, ethyl alcohol competitively inhibits alcohol dehydrogenase, an enzyme which catalyzes the metabolism of ethylene glycol and methanol to their toxic metabolites. In neurolysis, alcohol will destroy nerves at the site of injection.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131101\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Rapid </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution:  V<sub>d</sub>: 0.6-0.7 L/kg; decreased in women</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic (90% to 98%) to acetaldehyde or acetate </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Rate: 15-20 mg/dL/hour (range: 10-34 mg/dL/hour); increased in alcoholics </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Kidneys and lungs (~2% unchanged)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322968\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Foam</b> (DermaStat External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">65% (160 mL): $8.57</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Antiseptic Hand Rinse External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">62% (1.5 mL): $0.30</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Isagel External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60% (2.5 g): $0.24</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60% (621 mL): $8.17</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Medi-First Antiseptic Cleaner External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">66.5% (1.68 mL): $0.19</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Prevacare Antimicrobial External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60% (236 mL): $6.10</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (GelRite Hand Sanitizer External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">62% (118 mL): $1.87</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (ProtecTeaV External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">70% (60 mL): $4.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Alcohol Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">98% (5 mL): $117.50</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131107\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aogel (MX)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;American Academy of Pediatrics (AAP). Committee on Substance Abuse and Committee on Children With Disabilities, Fetal Alcohol Syndrome and Alcohol-Related Neurodevelopmental Disorders,&rdquo; <i>Pediatrics</i>, 2000, 106 (2):358-61. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ethanol-topical-and-injection-pediatric-drug-information/abstract-text/10920168/pubmed\" target=\"_blank\" id=\"10920168\">10920168</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barceloux DG, Bond GR, Krenzelok EP, et al, &ldquo;American Academy of Clinical Toxicology Practice Guidelines on the Treatment of Methanol Poisoning,&rdquo; <i>J Toxicol Clin Toxicol</i>, 2002, 40(4):415-46. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ethanol-topical-and-injection-pediatric-drug-information/abstract-text/12216995/pubmed\" target=\"_blank\" id=\"12216995\">12216995</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barceloux DG, Krenzelok EP, Olson K, Watson W. American Academy of Clinical Toxicology practice guidelines on the treatment of ethylene glycol poisoning. Ad Hoc Committee. <i>J Toxicol Clin Toxicol</i>. 1999;37(5):537-560. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ethanol-topical-and-injection-pediatric-drug-information/abstract-text/10497633/pubmed\" target=\"_blank\" id=\"10497633\">10497633</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blackwood RA, Klein KC, Micel LN, et al. Ethanol locks therapy for resolution of fungal catheter infections. <i>Pediatr Infect Dis J</i>. 2011;30(12):1105-1107.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ethanol-topical-and-injection-pediatric-drug-information/abstract-text/21844829 /pubmed\" target=\"_blank\" id=\"21844829 \">21844829 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cober MP, Johnson CE. Stability of 70% alcohol solutions in polypropylene syringes for use in ethanol-lock therapy. <i>Am J Health Syst Pharm</i>. 2007;64(23):2480-2482.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ethanol-topical-and-injection-pediatric-drug-information/abstract-text/18029955 /pubmed\" target=\"_blank\" id=\"18029955 \">18029955 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cober MP, Kovacevich DS, Teitelbaum DH. Ethanol-lock therapy for the prevention of central venous access device infections in pediatric patients with intestinal failure. <i>JPEN J Parenter Enteral Nutr</i>. 2011;35(1):67-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ethanol-topical-and-injection-pediatric-drug-information/abstract-text/20959638 /pubmed\" target=\"_blank\" id=\"20959638 \">20959638 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dannenberg C, Bierbach U, Rothe A, Beer J, K&ouml;rholz D. Ethanol-lock technique in the treatment of bloodstream infections in pediatric oncology patients with broviac catheter. <i>J Pediatr Hematol Oncol</i>. 2003;25(8):616-621.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ethanol-topical-and-injection-pediatric-drug-information/abstract-text/12902914 /pubmed\" target=\"_blank\" id=\"12902914 \">12902914 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dehydrated alcohool injection (alcohol, ethyl) [prescribing information]. Lake Forest, IL: Akorn, Inc; September 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hudak ML, Tan RC, Committee on Drugs, Committee on Fetus and Newborn, Americal Academy of Pediatrics (AAP). Neonatal drug withdrawal. <i>Pediatrics</i>. 2012;129(2):e540-560.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ethanol-topical-and-injection-pediatric-drug-information/abstract-text/22291123 /pubmed\" target=\"_blank\" id=\"22291123 \">22291123 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jones BA, Hull MA, Richardson DS, et al. Efficacy of ethanol locks in reducing central venous catheter infections in pediatric patients with intestinal failure.<i> J Pediatr Surg</i>. 2010;45(6):1287-1293.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ethanol-topical-and-injection-pediatric-drug-information/abstract-text/20620333 /pubmed\" target=\"_blank\" id=\"20620333 \">20620333 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Koren G, &ldquo;Drinking Alcohol While Breastfeeding. Will it Harm My Baby?&rdquo; <i>Can Fam Physician</i>, 2002, 48(5):39-41. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ethanol-topical-and-injection-pediatric-drug-information/abstract-text/11852608/pubmed\" target=\"_blank\" id=\"11852608\">11852608</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McGrath EJ, Salloum R, Chen X, et al. Short-dwell ethanol lock therapy in children is associated with increased clearance of central line-associated bloodstream infections. <i>Clin Pediatr (Phila)</i>. 2011;50(10):943-951. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ethanol-topical-and-injection-pediatric-drug-information/abstract-text/21622689 /pubmed\" target=\"_blank\" id=\"21622689 \">21622689 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mouw E, Chessman K, Lesher A, Tagge E. Use of an ethanol lock to prevent catheter-related infections in children with short bowel syndrome. <i>J Pediatr Surg</i>. 2008;43(6):1025-1029.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ethanol-topical-and-injection-pediatric-drug-information/abstract-text/18558177 /pubmed\" target=\"_blank\" id=\"18558177 \">18558177 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O'Grady NP, Alexander M, Burns LA, et al. Guidelines for the prevention of intravascular catheter-related infections. <i>Clin Infect Dis</i>. 2011;52(9):e162-193.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ethanol-topical-and-injection-pediatric-drug-information/abstract-text/21460264 /pubmed\" target=\"_blank\" id=\"21460264 \">21460264 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Onland W, Shin CE, Fustar S, Rushing T, Wong WY. Ethanol-lock technique for persistent bacteremia of long-term intravascular devices in pediatric patients. <i>Arch Pediatr Adolesc Med</i>. 2006;160(10):1049-1053.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ethanol-topical-and-injection-pediatric-drug-information/abstract-text/17018464 /pubmed\" target=\"_blank\" id=\"17018464 \">17018464 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pennington CR, Pithie AD. Ethanol lock in the management of catheter occlusion.<i> JPEN J Parenter Enteral Nutr</i>. 1987;11(5):507-508l.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pieroni KP, Nespor C, Ng M, et al. Evaluation of ethanol lock therapy in pediatric patients on long-term parenteral nutrition. <i>Nutr Clin Pract</i>. 2013;28(2):226-231.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ethanol-topical-and-injection-pediatric-drug-information/abstract-text/23232749 /pubmed\" target=\"_blank\" id=\"23232749 \">23232749 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ralls MW, Blackwood RA, Arnold MA, Partipilo ML, Dimond J, Teitelbaum DH. Drug shortage-associated increase in catheter-related blood stream infection in children. <i>Pediatrics</i>. 2012;130(5):e1369-1373. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ethanol-topical-and-injection-pediatric-drug-information/abstract-text/23045557 /pubmed\" target=\"_blank\" id=\"23045557 \">23045557 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reece-Stremtan S, Marinelli KA. ABM clinical protocol #21: guidelines for breastfeeding and substance use or substance use disorder, revised 2015. <i>Breastfeed Med</i>. 2015;10(3):135-141.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ethanol-topical-and-injection-pediatric-drug-information/abstract-text/25836677 /pubmed\" target=\"_blank\" id=\"25836677 \">25836677 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sachs HC, Committee On Drugs. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. <i>Pediatrics</i>. 2013;132(3):e796-809.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ethanol-topical-and-injection-pediatric-drug-information/abstract-text/23979084 /pubmed\" target=\"_blank\" id=\"23979084 \">23979084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Valentine KM. Ethanol lock therapy for catheter-associated blood stream infections in a pediatric intensive care unit.<i> Pediatr Crit Care Med</i>. 2011;12(6):e292-296.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ethanol-topical-and-injection-pediatric-drug-information/abstract-text/21499184 /pubmed\" target=\"_blank\" id=\"21499184 \">21499184 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wales PW, Kosar C, Carricato M, de Silva N, Lang K, Avitzur Y. Ethanol lock therapy to reduce the incidence of catheter-related bloodstream infections in home parenteral nutrition patients with intestinal failure: preliminary experience.<i> J Pediatr Surg</i>. 2011;46(5):951-956.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ethanol-topical-and-injection-pediatric-drug-information/abstract-text/21616259 /pubmed\" target=\"_blank\" id=\"21616259 \">21616259 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Werlin SL, Lausten T, Jessens, et al, &ldquo;Treatment of Central Venous Catheter Occlusions With Ethanol and Hydrochloric Acid,&quot; <i>JPEN J Parenter Enteral Nutr</i>, 1995, 19(5):416-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ethanol-topical-and-injection-pediatric-drug-information/abstract-text/8577023/pubmed\" target=\"_blank\" id=\"8577023\">8577023</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13289 Version 143.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F131116\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F131117\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1056328\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1056321\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F131096\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F131086\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1056332\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F25188563\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1056331\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F131139\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F131138\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F131102\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F131090\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298697\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6217619\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F131093\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F131105\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1056327\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1056330\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F131089\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F131101\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322968\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F131107\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13289|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ethanol-topical-and-injection-drug-information\" class=\"drug drug_general\">Ethanol (topical and injection): Drug information</a></li></ul></div></div>","javascript":null}